Physician profile
Ryan Reed
NPI 1912393166
$397.69
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.63 · 2022: $76.29 · 2023: $175 · 2024: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.08 | 2022-2024 | Xifaxan |
| La Jolla Pharmaceutical Company | $63.50 | 2022-2023 | Xerava |
| E.R. Squibb & Sons, L.L.C. | $40.63 | 2021 | |
| Boston Scientific Corporation | $38.74 | 2023-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $35.44 | 2023-2024 | |
| Abbvie INC. | $33.86 | 2023-2024 | |
| Pfizer INC. | $28.30 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.07 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $17.63 | 2023 | Dificid, Zerbaxa |
| Janssen Pharmaceuticals, INC | $14.44 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.